Please login to the form below

Not currently logged in
Email:
Password:

eptinezumab

This page shows the latest eptinezumab news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... Teva’s CGRP patent portfolio to develop, manufacture and commercialise

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....
01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...

Infographics